Cardiovascular manifestations of thalidomide embryopathy
Summary: More than 60 years after withdrawal of ConterganR (thalidomide) from the market, the issue is more relevant than ever for physicians specialised in vascular medicine and cardiology due to the age-related increased use of appropriate health services by those affected. We describe cardiovascu...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Article (Journal) |
| Lingua: | inglese |
| Pubblicazione: |
September 2025
|
| In: |
Vasa
Year: 2025, Volume: 54, Fascicolo: 5, Pages: 299-304 |
| ISSN: | 1664-2872 |
| DOI: | 10.1024/0301-1526/a001208 |
| Accesso online: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1024/0301-1526/a001208 Verlag, lizenzpflichtig, Volltext: https://econtent.hogrefe.com/doi/10.1024/0301-1526/a001208 
|
| Note sull'autore: | Peter Franz Klein-Weigel and Christina Ding-Greiner |
| Riassunto: | Summary: More than 60 years after withdrawal of ConterganR (thalidomide) from the market, the issue is more relevant than ever for physicians specialised in vascular medicine and cardiology due to the age-related increased use of appropriate health services by those affected. We describe cardiovascular abnormalities of thalidomide embryopathy and point out clinically relevant features that may have a profound influence on the disease management. We also describe and discuss whether arteriosclerotic diseases and complications occur more frequently in those affected by thalidomide embryopathy than in the general population. |
|---|---|
| Descrizione del documento: | Online veröffentlicht am: 2. Juli 2025 Gesehen am 22.06.2026 |
| Descrizione fisica: | Online Resource |
| ISSN: | 1664-2872 |
| DOI: | 10.1024/0301-1526/a001208 |